perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Validation of the ACMG/AMP guidelines-based seven-category variant 1

classification system 2

4 Jian-Min Chen^{1,*}, Emmanuelle Masson^{1,2}, Wen-Bin Zou^{3,4}, Zhuan Liao^{3,4}, Emmanuelle Génin,¹ 5 David N. Cooper⁵ and Claude Férec¹

6

3

7 ¹EFS, Univ Brest, Inserm, UMR 1078, GGB, F-29200 Brest, France. ²Service de Génétique Médicale et 8 de Biologie de la Reproduction, CHRU Brest, F-29200 Brest, France. ³Department of Gastroenterology, 9 Changhai Hospital, The Secondary Military Medical University, Shanghai, China. ⁴Shanghai Institute of 10 Pancreatic Diseases, Shanghai, China. ⁵Institute of Medical Genetics, School of Medicine, Cardiff 11 University, Cardiff, United Kingdom.

12

13 *Correspondence: Jian-Min Chen, MD, PhD, INSERM UMR1078 – EFS – UBO, 22 avenue Camille 14 Desmoulins, 29238 BREST, France. Email: jian-min.chen@univ-brest.fr

15

16 Abstract

17 Background: One shortcoming of employing the American College of Medical Genetics and 18 Genomics/Association for Molecular Pathology (ACMG/AMP)-recommended five-category variant classification scheme ("pathogenic", "likely pathogenic", "uncertain significance", "likely benign" and 19 20 "benign") in medical genetics lies in the scheme's inherent inability to deal properly with variants that 21 fall midway between "pathogenic" and "benign". Employing chronic pancreatitis as a disease model, and focusing on the four most studied chronic pancreatitis-related genes, we recently expanded the 22 23 five-category ACMG/AMP scheme into a seven-category variant classification system. With the 24 addition of two new classificatory categories, "predisposing" and "likely predisposing", our seven-25 category system promises to provide improved classification for the entire spectrum of variants in any 26 disease-causing gene. The applicability and practical utility of our seven-category variant classification 27 system however remains to be demonstrated in other disease/gene contexts, and this has been the 28 aim of the current analysis. 29 **Results:** We have sought to demonstrate the potential universality of pathological variants that could 30 be ascribed the new variant terminology ('predisposing') by trialing it across three Mendelian disease 31 contexts (i.e., autosomal dominant, autosomal recessive and X-linked). To this end, we firstly employed 32 illustrative genes/variants characteristic of these three contexts. On the basis of our own knowledge

33 and expertise, we identified a series of variants that fitted well with our "predisposing" category, including "hypomorphic" variants in the PKD1 gene and "variants of varying clinical consequence" in 34

- 35 the CFTR gene. These examples, followed by reasonable extrapolations, enabled us to infer the 36 widespread occurrence of "predisposing" variants in disease-causing genes. Such "predisposing" 37 variants are likely to contribute significantly to the complexity of human genetic disease and may 38 account not only for a considerable proportion of the unexplained cases of monogenic and oligogenic
- 39 disease but also for much of the "missing heritability" characteristic of complex disease.
- 40 Conclusion: Employing an evidence-based approach together with reasonable extrapolations, we
- 41 demonstrate both the applicability and utility of our seven-category variant classification system for
- 42 disease-causing genes. The recognition of the new "predisposing" category not only has immediate
- 43 implications for variant detection and interpretation but should also have important consequences for 44 reproductive genetic counseling.
- 45

46 **Keywords**

47 ClinGen, Clinical genetic testing, ClinVar, Conflicting interpretations of pathogenicity, Disease allele 48 frequency threshold, gnomAD, Haploinsufficiency, Incomplete penetrance, Variant reclassification,

49 VUS

⁵⁰ NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

Background 51

52 In 2015, the American College of Medical Genetics and Genomics/Association for Molecular Pathology 53 (ACMG/AMP) recommended a five-category scheme (namely, "pathogenic", "likely pathogenic", 54 "uncertain significance", "likely benign" and "benign") for classifying variants found in genes 55 underlying classical Mendelian disease entities [1]. This five-category scheme has since become widely 56 used in medical genetics (cited 17904 times according to Google Scholar as of 18 January 2023) despite 57 two fundamental limitations. First and foremost, this scheme was designed specifically to describe 58 variants in genes that cause monogenic Mendelian disorders. In other words, it was never intended to 59 be used to classify all variants in all disease-related genes. Moreover, even in the context of classical 60 Mendelian disease genes, the five-category scheme is inadequate to the task of coping with variants 61 that fall somewhere between "pathogenic" and "benign". In this regard, it is worth making two points. First, the "likely pathogenic" and "likely benign" categories should not be interpreted as denoting all 62 63 variants that fall somewhere between "pathogenic" and "benign"; rather, these two terms were 64 proposed by ACMG/AMP to "mean greater than 90% certainty of a variant either being disease-causing 65 or benign to provide laboratories with a common, albeit arbitrary, definition" [1]. Second, 66 ACMG/AMP's "uncertain significance" category is defined as EITHER when (i) criteria for "pathogenic", 67 "likely pathogenic", "benign" and "likely benign" are not met OR (ii) the criteria for benign and 68 pathogenic are contradictory. This ambiguity frequently causes confusion among clinicians, 69 researchers, genetic counselors and database curators alike.

70 The ACMG/AMP variant classification guidelines have been frequently adapted or refined to suit 71 different contexts (e.g., [2-17]). However, all these adaptations and refinements were made with 72 respect to the specific criteria or rules defining each of the five categories of the ACMG/AMP scheme. 73 The stepwise "ABC system" [18] was considered by its proponents to be an add-on or alternative to 74 the ACMG/AMP guidelines. However, one primary limitation of this system lies in its use of single letter 75 codes (i.e., A through F) for variant classificatory categories, which has made direct comparison with 76 the five-category ACMG/AMP scheme difficult and potentially rather confusing.

77 Employing chronic pancreatitis as a disease model and focusing on its four most studied genes, we 78 recently extended the five-category ACMG/AMP scheme into a general variant classification 79 framework [19]. In brief, we firstly divided the different genes into "disease-causing" and "disease-80 predisposing" based upon the integration of multiple layers of evidence with particular focus on their 81 different roles in the pathophysiology of the exocrine pancreas. We then employed two new 82 classificatory categories, "predisposing" and "likely predisposing", to expand and/or adapt the five-83 category ACMG/AMP scheme for disease-causing genes and disease-predisposing genes, respectively, 84 leading to the proposition of a two-branch general variant classification framework:

- 85 86
- A seven-category system (i.e., "pathogenic", "likely pathogenic", "predisposing", "likely predisposing", "uncertain significance", "likely benign" and "benign") for disease-causing genes.
- 87 88 89
- A five-category classification system (i.e., "predisposing", "likely predisposing", "uncertain significance", "likely benign" and "benign") for disease-predisposing genes.

90 Our two-branch general variant classification framework overcomes the limited scope of the five-91 category ACMG guidelines since it has the potential to span the entire spectrum of variants in any 92 disease-associated gene. In addition, our general variant classificatory framework has one additional 93 practical advantage: it retains the backbone of the five-category ACMG/AMP scheme, implying that 94 many ACMG/AMP-established rules and criteria for defining the primary variant classificatory 95 categories can be readily adapted or incorporated into our general framework.

96 The above notwithstanding, both the applicability and utility of our general variant classification 97 framework remain to be demonstrated in other disease/gene contexts. As the first step of this 98 endeavor, we explore herein the applicability and practical utility of the seven-category variant 99 classification system branch by trialing it across three classical Mendelian disease contexts (i.e., 100 autosomal dominant, autosomal recessive and X-linked). Employing a range of illustrative

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

3

101 disease/gene/variant examples and reasonable extrapolations, we demonstrate that our seven-102 category variant classification system has the potential to be widely applicable.

103

104 **Results**

105 Analytical rationale and strategy

Our seven-category variant classification system has two new categories, "predisposing" and "likely 106 107 predisposing", by comparison with the five-category ACMG/AMP guidelines [19]. With hindsight, these 108 two new categories may be regarded as being separated from ACMG/AMP's "uncertain significance" 109 category which, in our view, actually includes two distinct types of variant (Figure 1). The first of these 110 corresponds to those variants for which there is sufficient evidence to support their intermediate status somewhere between "pathogenic" and "benign", corresponding to our defined predisposing 111 112 category. The second refers to those variants for which there is insufficient evidence for any categorization, and which may be best described as being of "unknown significance". In the light of 113 114 this reflection, the "uncertain significance" category previously used in our general variant 115 classification framework was revised here to "unknown significance". In this regard, it is worth mentioning that both terms, "variant of unknown significance" and "variant of uncertain significance", 116 117 have been frequently used in the literature and both are abbreviated as "VUS".

118





Figure 1. Key differences between our seven-category system and the ACMG/AMP's five-category scheme. The two new classificatory categories (i.e., "predisposing" and "likely predisposing") in our seven-category variant classification system were considered here to be separated or split from the ACMG/AMP's "uncertain significance" category. The "uncertain significance" category previously used in our variant classification framework was also revised here to "unknown significance".

125 126

A comparison of our revised two-branch general variant classification framework with ACMG/AMP's five-category scheme is provided in Figure 2. The key to demonstrating the applicability and practical utility of our seven-category variant classification system is thus to demonstrate the general occurrence of pathological variants that can be unambiguously (or at least reasonably) allocated to one of the two new categories, "predisposing" and "likely predisposing".

132

medRxiv preprint doi: https://doi.org/10.1101/2023.01.23.23284909; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .



133

Widespread occurrence of "predisposing" variants

134 Figure 2. Illustration of the aims and analytical procedures adopted in this study. In the top panel, our 135 revised two-branch general variant classification framework is contrasted with ACMG/AMP's five-136 category scheme, with the two new classificatory categories, "predisposing" and "likely predisposing", 137 being highlighted in bold. The branch validated in the present study, the seven-category variant 138 classification system for disease-causing genes, is connected to the analytical procedures by a dotted 139 line. The validation focuses upon on the two new classificatory categories, which are highlighted in 140 bold and circled by horizontal ovals. ACMG/AMP, the American College of Medical Genetics and 141 Genomics/Association for Molecular Pathology; ADPKD, autosomal dominant polycystic kidney disease. 142 CFTR, cystic fibrosis transmembrane conductance regulator; PKD1, polycystin-1.

143 144

The terms "predisposing" and "likely predisposing" were proposed by analogy to ACMG/AMP's 145 146 terms "pathogenic" and "likely pathogenic" as well as "benign" and "likely benign". As such, "likely predisposing" should denote a greater than 90% certainty of a variant being predisposing. For the 147 148 purpose of establishing core principles, we shall not attempt to distinguish the two new categories, 149 "predisposing" and "likely predisposing", in the current analysis.

150 The "predisposing" category was only recently proposed by us [19]. No attempt had been made in previous studies to allocate variants into a "predisposing" category although the descriptor 151

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

5

152 "predisposing" has been frequently (and generally rather loosely) used in the literature to describe 153 pathologically significant variants. Faced with this situation, as well as the unrealistic prospect of being 154 able to analyze all relevant variants in all disease genes, we opted to adopt a simple practical approach. 155 As mentioned above, our proposed general variant classification framework was built upon sound data 156 from a single model disease, chronic pancreatitis, and its four most extensively studied genes [19]. In 157 similar vein, we shall herein attempt to build our case using illustrative genes/variants causing 158 respectively autosomal dominant, autosomal recessive and X-linked diseases. Findings from these 159 illustrative examples will finally be generalized so as to be applicable to all disease-causing genes.

160 Before delving into the details of our analysis (Figure 2), several points are worth noting. First, we initiated our analysis with variants in two genes underlying respectively an autosomal dominant 161 162 disease and an autosomal recessive disease, in both of which we have expertise [20-25]. Findings from these examples were then used to inform keyword searches in the context of X-linked diseases. We 163 164 would like to reiterate that these analytical procedures were intended to identify some but not all 165 pertinent examples. Second, pathologically relevant variants in the primary chronic pancreatitis-166 causing gene, *PRSS1* (OMIM #276000; encoding cationic trypsinogen), which originally prompted us to 167 propose the seven-category variant classification system, give rise to a gain of trypsin function or a 168 gain of proteotoxicity [19]. By contrast, the pathologically relevant variants that will be discussed below lead to the functional loss of their affected genes/proteins. In these disease genes, predicted 169 170 loss-of-function (i.e., nonsense, frameshift, large genomic deletion, and obligate splice site) variants 171 have almost invariably been classified as "pathogenic" whereas variants in regulatory or deep intronic 172 regions have often been classified as "benign" or "likely benign". By contrast, it is often difficult to 173 confidently classify missense variants appropriately without supporting functional data. Thus, not 174 surprisingly, the "predisposing" variants to be described below involve predominantly missense 175 variants. Third, "hypomorphic" (partial but not complete loss of function) variants in the genes to be 176 discussed below may also be considered to be "predisposing". However, "hypomorphic" variants in 177 some other gene/disease contexts may either be "pathogenic" or "benign" (a simple analogy may be 178 that while a complete loss-of-function variant in one gene may be harmless, in another gene it is 179 disease-causing). Moreover, to the best of our knowledge, there is no consensus with respect to a 180 threshold of partial functional loss as a means to define "hypomorphic". Fourth, we have not 181 performed any in silico predictions to assist the classification of missense variants owing to the 182 relatively poor overall performance of existing prediction tools in relation to this type of variant [26]. 183 Moreover, the functional effects of "predisposing" missense variants are in principle more refractory 184 to prediction than "pathogenic" missense variants (e.g., [27]). Lastly, selected variants will be 185 evaluated with respect to their classifications in ClinVar [28] and respective authoritative 186 disease/gene-specific databases, with a view to illustrating the dilemmas frequently encountered in 187 classifying this type of variant.

188

189 Autosomal dominant diseases

190 We selected autosomal dominant polycystic kidney disease (ADPKD) as a model of an archetypal 191 autosomal dominant disease. PKD1 (OMIM #601313), which encodes a 4303 amino acid receptor-like transmembrane protein, polycystin-1, is the primary causative gene for ADPKD located on 192 193 chromosome 16p13.3 [29, 30]. It has been subjected to extensive study since its identification nearly 194 30 years ago [31], with 2322 different variants being listed in the ADPKD Variant Database [32]. Of 195 particular relevance, all 815 truncating variants (i.e., frameshift, nonsense, obligate splice site and large 196 rearrangements) were classified by the ADPKD Variant Database as "pathogenic". By contrast, of the 197 782 missense variants, 277 have been classified as "likely pathogenic", 203 have been classified as 198 "VUS" and 302 have been classified as "likely benign". In other words, none of the 782 missense 199 variants have been classified as either "pathogenic" or "benign"; a reflection of the dire state of affairs 200 in which, as yet, no functional assay has been made available to ascertain the impact of PKD1 missense 201 variants.

202 Whilst *PKD1* haploinsufficiency due to rare heterozygous variants gives rise to ADPKD, the 203 inheritance of two ADPKD-causing *PKD1* alleles is a cause of recurrent fetal loss [33, 34]. Consistent

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

204 with this latter observation, *Pkd1* knockout mice are not viable embryonically [35]. However, mice homozygous for specific "hypomorphic" Pkd1 alleles developed polycystic kidney disease (PKD) and 205 206 were viable [36, 37]. Interestingly, human "hypomorphic" PKD1 variants have also been reported in 207 the literature, in both a homozygous and compound heterozygous context. Such variants reported up 208 until the middle of 2014 [38-42], which were previously reviewed by us [22], will be used here as 209 illustrative examples (Table 1). Specifically, all three individuals homozygous for PKD1 hypomorphic 210 variants presented with PKD whereas the corresponding heterozygotes had no or only a few renal cysts. 211 As far as the compound heterozygotes were concerned, two situations were evident. In the first, both 212 variants were missense, with all single heterozygotes being unaffected whilst all compound 213 heterozygotes presented with PKD. In the second situation, the compound heterozygotes comprised 214 a missense variant and an unambiguous pathogenic variant; all missense variant heterozygotes were 215 unaffected but all compound heterozygotes were characterized by severe PKD. Presumably, these 216 "hypomorphic" missense variants caused a partial functional loss of the affected allele, albeit a loss 217 that, in simple heterozygosity, did not result in the threshold of PKD causation being breached. 218 However, these variants, when inherited either in the homozygous or compound heterozygous state, 219 reduced PKD1 function to a level below that of the disease-causing threshold. One such missense 220 variant, p.Arg3277Cys (detected once as a homozygote and twice as a compound heterozygote (Table 1)), was studied in a knock-in mouse model. The homozygous knock-in mice were estimated to exhibit 221 222 ~40% of the Pkd1 function of wild-type mice [43]. This suggests that a simple p.Arg3277Cys 223 heterozygote (not PKD-causing) would be expected to retain 70% of normal PKD1 function (i.e. 20% 224 higher than the 50% PKD1 function in heterozygotes carrying a typical "pathogenic" PKD1 variant).

- 225 Keyword searches in PubMed using "PKD1" plus "homozygote", "incomplete penetrant", "hypomorphic", "biallelic" or "trans heterozygous" identified further studies reporting PKD1 226 227 "hypomorphic" variants [44-49]. Notably, the Durkie study reported a high prevalence of biallelic 228 inherited "hypomorphic" PKD1 variants in very early onset PKD [48]. Of particular relevance, Durkie 229 and colleagues discussed the various difficulties encountered in classifying this particular type of PKD1 230 variant. First, they considered that it was challenging to use the current ACMG/AMP variant 231 classification guidelines to classify PKD1 "hypomorphic" variants as these variants "do not function as 232 classic loss-of-function variants causing autosomal dominant disease" [48]. Moreover, they also 233 regarded the additional terms (i.e., "reduced penetrance" and "ultralow penetrance") used in the 234 literature to describe this kind of variant [50] as confusing. Further, they considered the ClinGen 235 Consortium Low Penetrance/Risk Allele Working Group-recommended terminology for describing 236 reduced penetrance variants, namely the use of the ACMG/AMP categories plus a quantitative descriptor (i.e., "likely pathogenic, low penetrance" or "likely pathogenic, reduced penetrance"), to be 237 238 inappropriate for describing PKD1 "hypomorphic" variants; "the scenario for PKD1 hypomorphic 239 variants that cause cysts only when inherited in trans with another pathogenic or hypomorphic variant 240 does not fall under this definition" [48].
- Facing the abovementioned difficulties, Durkie and colleagues opted to use "3H" (the 3 refers to ACMG/AMP's "uncertain significance" category whilst H denotes "hypomorphic") for the classification of the "hypomorphic" *PKD1* variants [48]. Finally, Durkie et al. noted that hypomorphic variants are not unique to *PKD1* and cited several additional disease/gene examples with this type of variant (viz. maturity-onset diabetes of the young (MODY)/*HNF1A* [51], *RFX6* [52] and *HNF4A* [53]; Parkinson's disease/*VPS35* [54] and *LRRK2* [55]; retinal dystrophy/*ABCA4* [56]; and Joubert syndrome/*SUFU* [57]). As shown in Table 1, the illustrative examples of "hypomorphic" *PKD1* variants were often classified
- as "VUS" in the ADPKD variant database [32] and as "VUS" or "conflicting interpretations of pathogenicity (CIP)" in ClinVar [28]. Our proposed "predisposing" category provides a perfect fit for the "hypomorphic" *PKD1* variants. Intuitively, findings from the "hypomorphic" *PKD1* variants can be generalized to all autosomal dominant diseases owing to haploinsufficiency (Figure 3).

252 **Table 1.** Illustrative examples of "hypomorphic" *PKD1* variants*

Variant(s) ^a	Reference	Classification	
		ADPKD variant database	ClinVar
Homozygote			
c.[3133G>A;4709C>T]	[38]	p.Val1045Met, VUS;	p.Val1045Met, NA;
(p.[Val1045Met;Thr1570Met])		p.Thr1570Met, VUS	p.Thr1570Met, CIP (P × 1, VUS × 1)
c.9563A>G (p.Asn3188Ser)	[39]	p.Asn3188Ser, VUS	p.Asn3188Ser, NA
c.9829C>T (p.Arg3277Cys)	[39]	p.Arg3277Cys, VUS	p.Arg3277Cys, CIP (P × 4, LP × 2, VUS × 2)
Compound heterozygote			
c.[3312dupC];[6749C>T]	[40]	p.Thr2250Met, likely benign	p.Thr2250Met, CIP (VUS × 2, B × 1, LB × 1)
(p.[Val1105fs] ;[Thr2250Met])			
c.[3820G>A];[3820G>A;8716G>A]	[41]	p.Val1274Met, VUS;	p.Val1274Met, NA;
(p.[Val1274Met];[Val1274Met;Gly2906Ser])		p.Gly2906Ser, likely benign	p.Gly2906Ser, VUS (single submitter)
c.[4199delT];[12413G>A]	[41]	p.Arg4138His, VUS	p.Arg4138His, NA
(p.[Leu1400fs];[Arg4138His])			
c.[6472C>T];[9829C>T]	[39]	p.Arg3277Cys, VUS	p.Arg3277Cys, CIP (P × 4, LP × 2, VUS × 2)
(p.[Gln2158*];[Arg3277Cys])			
c.[6658C>T];[9829C>T]	[38]	p.Arg2220Trp, VUS;	p.Arg2220Trp, VUS (single submitter)
(p.[Arg2220Trp];[Arg3277Cys])		p.Arg3277Cys, VUS	p.Arg3277Cys, CIP (P × 4, LP × 2, VUS × 2)
c.[7915_7916ins20];[8293C>T]	[39]	p.Arg2765Cys, VUS	p.Arg2765Cys, CIP (VUS × 3, B × 2, LB × 1)
(p.[Arg2639fs];[Arg2765Cys])			
c.[8259C>G];[6763C>T]	[41]	p.Arg2255Cys, VUS	p.Arg2255Cys, NA
(p.[Tyr2753*];[Arg2255Cys])			
c.[8293C>T];[9313C>T]	[39]	p.Arg2765Cys, VUS;	p.Arg2765Cys, CIP (VUS × 3, B × 2, LB × 1);
(p.[Arg2765Cys];[Arg3105Trp])		p.Arg3105Trp, VUS	p.Arg3105Trp, VUS (VUS × 2)
c.[8362_8363ins34];[5848G>A]	[42]	p.Val1950Met, VUS	p.Val1950Met, VUS (single submitter)
(p.[Ser2788fs];[p.Val1950Met])			
c.[11457C>A];[8293C>T]	[39]	p.Arg2765Cys, VUS	p.Arg2765Cys, CIP (VUS × 3, B × 2, LB × 1)
(p.[Tyr3819 *];[Arg2765Cys])			

ADPKD, autosomal dominant polycystic kidney disease; B, benign; CIP, conflicting interpretations of pathogenicity; LB, likely benign; LP, likely pathogenic;


254 NA, not available; P, pathogenic; VUS, variant of uncertain (unknown) significance.

255 *Variants previously reviewed in [22].

^aDefinite pathogenic variants are highlighted in bold.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .





257

Figure 3. "Predisposing" variants in autosomal dominant diseases caused by haploinsufficiency. This model was generalized from the so-called "hypomorphic" *PKD1* variants. Disease (1), disease caused by a typical "pathogenic" variant leading to the complete or almost complete loss of the affected allele. Disease (2) and disease (3) represent two situations in which the disease is caused by a combination of two "predisposing" variants.

263 264

265 There is one final point to make. In classical Mendelian diseases, disease prevalence has been 266 employed to estimate a maximum allele frequency threshold for a "pathogenic' variant (e.g., [58-62]). 267 The prevalence of ADPKD in Europe and USA is no higher than 5 in 10,000 inhabitants [63, 64]. This 268 means that a typical PKD1 "pathogenic" variant (leading to the complete or almost complete loss of 269 the affected allele) cannot exceed an allele frequency of 0.00025 in the corresponding normal 270 population. However, a PKD1 "hypomorphic" variant may exceed such a maximal allele frequency 271 threshold owing to the absence of an associated clinical phenotype in the heterozygous state [48]. For 272 example, the highest sub-population allele frequency (i.e., 0.0004532 [65]) of the aforementioned 273 PKD1 p.Arg3277Cys variant was found in the non-Finnish European population. This is ~1.8 fold higher 274 than the estimated maximum allele frequency of 0.00025 for a typical PKD1 "pathogenic" variant in Europeans. In short, some pathologically relevant "hypomorphic" variants are likely to have been 275 276 inadvertently filtered out using the maximal allele frequency threshold established for a typical 277 "pathogenic' variant.

278

279 Autosomal recessive diseases

280 We selected cystic fibrosis (CF) [66] as an archetypal autosomal recessive disease. CFTR (cystic fibrosis 281 transmembrane conductance regulator; OMIM #602421) is the sole causative gene for CF [67]. The 282 gene is located on chromosome 7q31.2, contains 27 exons and encodes a 1480 amino acid protein. 283 Whereas the Cystic Fibrosis Mutation Database (CFTR1) [68] lists 2110 CFTR variants reported until Apr 284 25, 2011, the Clinical and Functional TRanslation of CFTR (CFTR2) database lists 485 variants with 285 detailed genotype-phenotype information gathered from CF patient registries around the world [69] 286 (CFTR2 is led by a team of world-renowned researchers and clinicians, who are seeking to provide 287 expert-reviewed functional and clinical information on CFTR mutations). These 485 variants were 288 classified by CFTR2 into four categories, with the category definitions and number of variants in each category being provided in Table 2. CFTR2 uses the term "varying clinical consequence (VCC)" to 289 290 describe 49 variants that were deemed not to correspond to any of the five ACMG/AMP-defined 291 variant categories; "If CF is the defined phenotype for which ACMG-AMP guidelines are being applied, 292 it might be difficult to assign these variants as pathogenic or likely pathogenic (without clear evidence 293 of CF in some people), but the term VUS is not appropriate because, in many cases, clinical significance 294 is not uncertain" [27].

medRxiv preprint doi: https://doi.org/10.1101/2023.01.23.23284909; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license .

295

Table 2. Summary of the 485 CFTR2-annotated CFTR variants 296

Classification	Definition	Number of variants
CF-causing	The variant in question "causes CF 401	
	when combined with another CF-	
	causing variant".	
Varying clinical	The variant in question "has varying	49
consequence	consequences. Some patients with the	
	variant, combined with another CF-	
	causing variant, have CF. Other	
	patients with the variant, combined	
	with another CF causing variant, do	
	not have CF".	
Non CF-causing	The variant in question "DOES NOT	24
	cause CF when combined with	
	another CF-causing variant".	
Unknown significance	The variant in question "is still under	11
	evaluation. At this time, the CFTR2	
	team does not have enough	
	information to determine whether or	
	not it causes CF".	

297 CF, cystic fibrosis; CFTR, cystic fibrosis transmembrane conductance regulator; CFTR2, the Clinical and 298 Functional TRanslation of CFTR database.

299

300

301 Importantly, a comprehensive functional assay of 48 selected CFTR missense variants with 302 variable expressivity of CF in a native isogenic context revealed that CF-causing (n = 24), VCC (n = 16) 303 and non-CF-causing (n = 6) missense variants displayed <10%, 10-75% and >75% of wild-type CFTR 304 function, respectively. The simplest biological mechanism responsible for the pathological impact of 305 these VCC variants would involve a reduction in expression of the affected CFTR alleles so as to reach 306 the CF-causing threshold level. This could come about if these variants (i) were combined with 307 variants that served to reduce CFTR expression in modifier genes, (ii) interacted with environmental 308 factors or (iii) were in cis with an as yet unidentified functional variant that served to further reduce 309 CFTR expression [27, 70]. With regard to the latter, it is important to emphasize that even in the rare 310 instances of reports describing "complete CFTR gene sequencing" [71, 72], variants identified in deep intronic and remote regulatory regions have not been subjected to thorough evaluation. 311

312 Of the 16 functionally characterized VCC variants, nine have been shown to retain 10% to 25% of 313 wild-type CFTR function [27]. These nine variants are employed here as illustrative examples with 314 respect to ClinVar classifications. All these variants, with the exception of p.Asp110Glu, were

315 classified as having CIP (Table 3).

316 Again, our proposed "predisposing" category would offer a perfect fit for the CFTR2-defined VCC variants. Findings from the illustrative CFTR/CF studies were generalized into classical autosomal 317 recessive diseases that were caused by loss-of-function variants (Figure 4). 318

319

medRxiv preprint doi: https://doi.org/10.1101/2023.01.23.23284909; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

10


Table 3. Illustrative examples of CFTR2-annotated variants with "varying clinical consequence"* 320

Variant		ClinVar classification
cDNA name	Protein name	
c.14C>T	p.Pro5Leu	CIP (P × 3; LP × 6; VUS × 2)
c.330C>A	p.Asp110Glu	Drug response (P × 5; LP × 2; VUS × 1; drug response × 1)
c.794T>G	p.Met265Arg	CIP (P × 1; LP × 3; VUS × 2)
c.1724T>A	p.Phe575Tyr	CIP (P × 1; LP × 1; VUS × 6)
c.1865G>A	p.Gly622Asp	CIP (P × 9; LP × 7; VUS × 2; B × 1)
c.3095A>G	p.Tyr1032Cys	CIP (P × 6; LP ×6; VUS ×1)
c.3297C>A	p.Phe1099Leu	CIP (P × 2); LP ×1; VUS ×6)
c.3458T>A	p.Val1153Glu	CIP (P × 1; VUS × 3)
c.3737C>T	p.Thr1246Ile	CIP (P × 5; LP × 2; VUS ×2)

321 B, benign; CIP, conflicting interpretations of pathogenicity; LP, likely pathogenic; P, pathogenic; VUS, 322 variant of uncertain (unknown) significance.

*These variants are characterized by >10% but <25% of wild-type CFTR function [27]. 323

- 324
- 325



326

Figure 4. "Predisposing" variants in autosomal recessive diseases caused by loss-of-function variants. 327 This model was generalized from CFTR variants with "varying clinical consequence" related to 328 329 autosomal recessive cystic fibrosis. In disease situation 1, the disease manifests as typical autosomal 330 recessive inheritance. In disease situation 2, the "predisposing" variant must interact with additional 331 variant(s) in modifier genes and/or with environmental factors in order for the disease to be expressed clinically. Alternatively, an as yet unidentified variant may exist in *cis* that serves to further reduce the 332 333 function of the "predisposing" allele. The curved arrow points to a situation in which the "predisposing" 334 variant can be "pathogenic" for an atypical or related milder disease.

- 335
- 336

337 The CFTR VCC variants that displayed 10-75% of wild-type CFTR function may be termed 338 "hypomorphic" by comparison to the CF-causing and non-CF-causing variants. Whilst these VCC 339 variants were "predisposing" with respect to CF, they may be "pathogenic" with respect to CFTR-340 related disorders (clinical entities with features of CF and evidence for the presence of CFTR 341 dysfunction but not meeting the full criteria for diagnosis of CF) [73]; this may be one reason for the 342 often encountered "conflicting interpretations of pathogenicity" in ClinVar with respect to the CFTR 343 VCC variants. This possibility is also illustrated in Figure 4.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

344 X-linked diseases

Whereas females have paired X chromosomes, males possess only a single X chromosome. Moreover, in females, the possession of two X chromosomes leads to a dosage issue which is compensated for by X-inactivation [74, 75]. These two unique properties often blur the standard definitions of dominance and recessiveness in X-linked diseases. Indeed, it has even been recommended that "use of the terms X-linked recessive and dominant be discontinued, and that all such disorders be simply described as following "X-linked" inheritance" [76].

Mindful of the difficulties encountered in analyzing X-linked genes/variants, we sought to use the 351 352 findings from the abovementioned PKD1 variants to guide our analysis in the context of X-linked 353 dominant diseases. We began our analysis with X-linked dominant diseases in females, which can be 354 analogous to autosomal dominant diseases. Given that the abovementioned "predisposing" PKD1 355 variants were found in either a homozygous or compound heterozygous state, we postulated that homozygous or compound heterozygous variants found in females with a seemingly typical X-linked 356 357 dominant disease have a high probability of falling into the "predisposing" category. More specifically, 358 the vast majority of female patients with an X-linked dominant condition will be heterozygotes 359 whereas homozygous or compound heterozygous individuals would generally be extremely rare. 360 Therefore, when a homozygous or compound heterozygous individual is encountered, each allele is likely to be hypomorphic because on their own they are insufficient to result in a clinical phenotype. 361 To identify such variants, we performed a keyword search in PubMed using "X-linked dominant" plus 362 "homozygote", "homozygous", "hypomorphic", "compound heterozygote" or "biallelic". We identified 363 a single candidate homozygous variant that was originally reported in a 30-month-old Indian girl with 364 365 suspected Rett syndrome (RS) [77]), which will be discussed in detail below.

366 RS is a severe early onset neurological condition that occurs almost exclusively in females. It is 367 usually inherited in an X-linked dominant manner and is primarily caused by *de novo* heterozygous 368 mutations in the MECP2 gene [78-80]. Males with RS-causing MECP2 mutations have severe neonatal 369 encephalopathy that is usually lethal whilst those with non-RS-causing MECP2 mutations can 370 demonstrate a wide variety of neurological disorders [81]. In the light of findings from the 371 PKD1/ADPKD system, some of these non-RS-causing MECP2 variants may be assumed to represent 372 "hypomorphic" (partial but not complete functional loss) variants as compared to the typical RS-373 causing MECP2 variants (complete or almost complete functional loss). Further, some "hypomorphic" 374 variants may be clinically asymptomatic in heterozygous females but cause disease in the homozygous 375 or compound heterozygous state.

376 The above-mentioned homozygous MECP2 variant identified in a girl with suspected RS was 377 c.1160C>T (p.Pro387Leu) according to NM 004992.4 or c.1196C>T (p.Pro399Leu) according to 378 NM 001110792.2. Her mother did not carry this variant nor any other mutation in the MECP2 gene. 379 Her father, who carried the MECP2 p.Pro399Leu variant, was reported not to exhibit any indication of 380 intellectual disability [77]. The MECP2 p.Pro399Leu variant had been reported in two studies prior to 381 the Bhanushali report [77]. In the first, the variant was identified in a male patient with sporadic 382 intellectual disability [82]. In the second study, the variant (zygosity not reported but presumably 383 heterozygous) was identified in a female RS patient; it was however deemed to have no pathological 384 relevance owing to its presence in the healthy father [83].

385 Herein, we further surveyed the MECP2 p.Pro399Leu variant in ClinVar [28]. Only in one of the 386 seven submissions of this variant was the affected status indicated as "yes" (accession SCV000187889.2). In this single "yes" case, the disorder of the corresponding male patient was 387 388 diagnosed as "mental retardation, X-linked, syndromic 13" with the MECP2 variant being of maternal 389 origin. In short, of the aforementioned four male carriers of the MECP2 p.Pro399Leu variant, two (50%) 390 were reported to exhibit intellectual disability. These limited data may nevertheless be consistent with MECP2 p.Pro399Leu being a pathologically relevant but "hypomorphic" variant, taking into account 391 392 the observation that this variant (i) is very rare in the combined gnomAD (the Genome Aggregation 393 Database) male subjects (carrier/allele frequency, 0.00009947 [65]) and (ii) was identified in a gene 394 known to be responsible for various neurological conditions.

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

12

In ClinVar [28], the *MECP2* p.Pro399Leu variant was classified as "benign", "likely benign" and "uncertain significance" by two, three and two submitters, respectively; collectively, it was classified as "benign". Some submitters provided detailed evidence supporting their classification, with two examples being cited as below;

- Benign, accession SCV002047342.1. "The allele frequency of the p.Pro387Leu (NM_004992.3) variant in MECP2 is 0.026% in South Asian sub-population in gnomAD, which is high enough to be classified as likely benign based on thresholds defined by the ClinGen Rett/Angelman-like Expert Panel for Rett/AS-like conditions (BS1)" ClinGen Rett and Angelman-like Disorders Variant Curation Expert Panel.
- Likely benign, accession SCV000698534.2. "This variant was found in 17/186675 control chromosomes (gnomAD) at a frequency of 0.0000911, which is approximately 11 times the estimated maximum expected allele frequency of a pathogenic MECP2 variant (0.0000083), suggesting this variant is likely a benign polymorphism." Women's Health and Genetics/Laboratory Corporation of America, LabCorp.

409 The above two submitters classified the *MECP2* p.Pro399Leu variant as "benign" or "likely benign" 410 based primarily upon the maximal disease allele frequency threshold that was estimated for a 411 "pathogenic" MECP2 variant with respect to typical RS. As with the case of the previously discussed 412 "hypomorphic" PKD1 p.Arg3277Cys variant, this practice was clearly inappropriate for classifying the 413 "hypomorphic" MECP2 p.Pro399Leu variant. To better understand this issue, we re-evaluated the 414 prevalence of typical RS and the allele frequency of MECP2 p.Pro399Leu in gnomAD populations. In 415 this regard, it is important to emphasize that whereas hemizygous MECP2 p.Pro399Leu males may 416 exhibit intellectual disability, heterozygous MECP2 p.Pro399Leu females appear almost invariably to 417 be healthy. Thus, to be maximally relevant to our thesis, we re-evaluated these data only in the context 418 of females. The prevalence of classical RS was, at most, one in 10,000 females [84], which corresponds 419 to a maximum allele frequency of 0.00005 for a typical RS-causing MECP2 variant. The allele frequency 420 of MECP2 p.Pro399Leu in gnomAD-analyzed females was 0.00006474 [65], which is ~1.3-fold higher 421 than 0.00005 (it should be remembered that the corresponding ratio for the "hypomorphic" PKD1 422 p.Arg3277Cys variant was ~1.8). Moreover, it should be emphasized that no MECP2 p.Pro399Leu 423 homozygotes were found in the 61,785 gnomAD-derived females [65].

Taken together, it is not unreasonable to conclude that *MECP2* p.Pro399Leu represents a "hypomorphic" variant that gives rise to intellectual disability in males (with 50% penetrance) in the hemizygous state whilst causing RS in females only in the homozygous state. Bearing this in mind, we may speculate that the previously reported female RS patient carrying a heterozygous *MECP2* p.Pro399Leu [83] may harbor an as yet unidentified "hypomorphic" or "predisposing" variant in the other *MECP2* allele.

430 Examples of the RS-causing and non-RS-causing variants in the MECP2 gene may logically imply 431 similar situations in some other X-linked genes, in which heterozygous pathogenic variants (causing 432 complete or almost complete functional loss of the affected allele) in females cause typical X-linked 433 dominant diseases whilst hemizygous "hypomorphic" variants in males (complete or almost complete 434 functional loss is lethal to males) cause a related phenotype; such "hypomorphic" variants may not be 435 associated with a clinical phenotype when found in females in the heterozygous state but will cause 436 disease in females when found in homozygosity or compound heterozygosity. We performed a keyword search in PubMed using "X-linked male female hypomorphic", identifying multiple X-linked 437 438 genes that appear to be compatible with the above situation (e.g., EBP [85], NAA10 [86], BCOR [87], 439 NSDHL [88], IKBKG [89], DDX3X [90] and CASK [91]).

440

441 Widespread occurrence and clinical importance of disease "predisposing" variants

442 The aforementioned examples of loss-of-function variants, together with our previously discussed 443 gain-of-function and gain of proteotoxicity *PRSS1* variants in chronic pancreatitis [19], would logically


444 imply the widespread occurrence of "predisposing" variants in most, if not all, disease-causing genes.

- 445 Our argument presupposes that mutations can potentially occur anywhere in the human genome but
- also that the functional impact of variants is diverse depending upon their location and type. It follows

medRxiv preprint doi: https://doi.org/10.1101/2023.01.23.23284909; this version posted January 25, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.

447 that the pathological relevance of variants in any disease-causing gene is dependent upon their 448 functional effect. Thus, in disease-causing genes, three principal categories of variant, namely "pathogenic", "predisposing" and "benign", are likely to occur (Figure 5). To reinforce this concept, we 449 450 cite two additional disease/gene examples. Huntington's disease is caused predominantly by an expansion of trinucleotide CAG repeats in the huntingtin gene (HTT; OMIM #613004) [92]. 451 Huntington's disease is a true autosomal dominant condition because the clinical phenotype of a 452 homozygote is indistinguishable from that of a heterozygote [93]. Nonetheless, it is the number of CAG 453 454 repeats that determines the age of onset of disease, as well as its progression and severity. Fewer than 455 27 CAG repeats are asymptomatic whereas \geq 40 CAG repeats invariably cause the disease [94]. Lying in 456 between is an intermediate category comprising a series of CAG repeats of varying size, some of which 457 may be classified as 'predisposing'. The second example is the fragile X syndrome/FMR1 CGG repeat 458 expansion [95]. In unaffected individuals in the general population, the number of CGG repeats in the 459 5'-untranslated region of FMR1 is fewer than 55. In patients with fragile X syndrome, however, the 460 number of CGG repeats invariably exceeds 200. Although individuals with 55-200 CGG repeats are 461 clinically asymptomatic, these 'premutation carrier' individuals are predisposed to fragile X syndrome 462 since CGG repeats in the range 55-200 are prone to expand into the pathological range [96].

463 464



465

Figure 5. Widespread occurrence and clinical importance of "predisposing" variants. As for disease 466 467 complexity, the illustrated situations should not be interpreted as representing all possible 468 eventualities.

469

470

471 The importance of recognizing the new "predisposing" category, in both research and clinical contexts cannot be overstated, as "predisposing" variants are primarily responsible for the complexity 472 473 of human genetic disease. In other words, the genetic basis of health and disease would be quite 474 straightforward if all variants were either "pathogenic" or "benign". It is difficult to list all possible

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

475 contributions of "predisposing" variants to human genetic disease complexity, but some are illustrated 476 in Figure 5. Thus, in the context of an autosomal dominant disease, the disease may appear earlier and 477 be more severe if a "predisposing" variant occurs in trans or cis with a "pathogenic" variant in the same 478 disease gene; further, the combination of two individually harmless "predisposing" alleles within the 479 same gene may result in a typical or even a severe form of the disease. Moreover, a given disease may 480 be regarded as essentially monogenic despite the involvement of modifier genes (one illustrative 481 example might be a CF patient carrying a pathogenic CFTR allele, a "predisposing" CFTR allele and a variant in an unlinked modifier gene [97]). Further, two "predisposing" variants in independent but 482 483 mechanistically linked disease-causing genes (e.g., ADPKD-causing PKD1 and PKD2 [48, 98]) may also 484 be envisaged to cause a typical digenic disease. Finally, "predisposing" variants in a disease-causing 485 gene may even contribute to disease under a polygenic inheritance or complex model (e.g., [99]).

The recognition of the new "predisposing" category will also have pivotal consequences for reproductive genetic counseling. For example, a couple each carrying a *bona fide* "predisposing" variant in an autosomal dominant disease-causing gene, could give birth to a clinically affected child. Litigation might ensue if such variants were to be inadequately and perfunctorily ascribed the descriptor "VUS" during antenatal genetic counselling.

491

492 **Discussion**

493 Both the "hypomorphic" *PKD1* variants and the *CFTR* variants of "varying clinical consequence" serve 494 to illustrate our dilemma in classifying clinically detected variants using the ACMG/AMP-recommended 495 five-category scheme. We propose that this dilemma may now be resolved by adopting a new 496 classificatory scheme with a new variant term, "predisposing".

Based upon existing knowledge and reasonable extrapolations, we infer the presence of "predisposing" variants in most, if not all, disease-causing genes. Although this analysis focused upon loss-of-function variants, "predisposing" variants can have other functional consequences, e.g. gainof-function or gain of proteotoxicity, depending upon the gene responsible and the underlying disease mechanism. Here, it is worth reiterating that the study of gain-of-function and gain of proteotoxicity *PRSS1* variants contributed to the proposition of our general variant classification framework [19].

503 Various examples of "hypomorphic" PKD1 variants were identified through the study of 504 exceptional families on the one hand and the availability of renal cysts as a reliable and objective 505 diagnostic criterion for PKD on the other. Examples of CFTR VCC variants were identified through the 506 careful evaluation of CF patients worldwide by the CFTR2 International Initiative. Since "predisposing" variants have by definition less profound effects than standard "pathogenic" variants, we may infer 507 508 that many "predisposing" variants are likely to have been overlooked in both a research and a clinical 509 setting. In this regard, it is pertinent to cite the examples of the abovementioned PKD1 p.Arg3277Cys 510 and MECP2 p.Pro399Leu variants, both of which should theoretically have been filtered out by 511 reference to the maximum allele frequency expected for a typical pathogenic variant in these disorders. 512 As such, "predisposing' variants, which can potentially include any type of variant (e.g., missense, 513 intronic, regulatory), may not only account for a significant fraction of the unexplained cases of both 514 monogenic and oligogenic disease [100-103] but may also be relevant to the "missing heritability" 515 problem in complex disease [104, 105].

As illustrated in Figure 1, our new classificatory categories could be considered to be separated or spit from ACMG/AMP's "uncertain significance" category, further facilitating the practical application of our seven-category variant classification system. Specifically, variants falling into the "predisposing" category should be predominantly present within the variants of "uncertain significance" that were classified according to the ACMG/AMP's five-category scheme. A variant can be classified as "predisposing" if and when there is sufficient genetic and/or functional evidence to support such a classification; otherwise, one can always retain the VUS classification.

523 The above notwithstanding, in practice, one often has to make fairly arbitrary decisions with regard 524 to separating "predisposing" variants from "pathogenic" and "benign" variants. This is a difficult but 525 unavoidable task, and generally involves making arbitrary decisions with respect to the definitions of

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

"likely pathogenic" and "likely benign" variants as well as the thresholds used for defining "high", 526 "moderate" or "low" penetrance. In this regard, it is pertinent to cite the "ABC" system, whose A, B 527 528 and C categories all refer to "pathogenic" variants, albeit with differences in terms of their penetrance 529 [18]. Moreover, the ClinGen Low-Penetrance/Risk Allele Working Group aims to develop a consensus 530 with regard to the terminology required to categorize both risk alleles and low-penetrance Mendelian 531 variants and to develop a standardized classification framework to evaluate these types of variant 532 [106]. In our view, variants with a penetrance below a given threshold (e.g., 20%) may be more appropriately classified as "predisposing" rather than "pathogenic". Nonetheless, given the intrinsic 533 534 complexity of biology and disease, we would recommend that such decisions "need to be made on a 535 gene-by-gene basis and would require close collaboration between researchers and clinicians with 536 specific expertise in the diseases/genes in question" [19]. This need becomes even more pressing if we 537 consider that (i) the same variant may be "predisposing" in the context of a typical disease but 538 "pathogenic" in the context of a related atypical disease (e.g., CFTR VCC variants in CF and CFTR-related 539 diseases) and (ii) variants in a given gene can potentially contribute to a disease that can manifest as 540 monogenic, digenic/oligogenic or even multifactorial (e.g., chronic pancreatitis [19, 107]).

541 Over the past years, we have witnessed near continuous revolution in terms of the standards and 542 rules governing how to weigh and combine evidence with a view to improving our classification of 543 variants, as reflected by the abovementioned works that have attempted to adapt or refine the 544 ACMG/AMP guidelines [2-17]. Directly or indirectly related to these adaptations or refinements, 545 variant reclassifications (either upgrades or downgrades) have been a frequent occurrence in the 546 literature (e.g., see recent reports [108-118]. It is our hope that our proposed general variant 547 classification framework will stimulate discussion and debate and lead to further improvements in 548 variant classification.

549

555

558

561

550 **Conclusions**

In this analysis, we present cogent arguments in support of the applicability and utility of our sevencategory variant classification system for disease-causing genes. The recognition of the new "predisposing" category not only has important implications for variant detection and interpretation but should also have important consequences for reproductive genetic counseling.

556 **Competing interests**

557 The authors have no conflicts of interest to declare that are relevant to the content of this article.

559 Funding

560 This study did not receive any specific financial support.

562 Authors' contributions

563 J.M.C. conceived and designed the study, performed the literature search, prepared all tables and 564 figures and drafted the manuscript. E.M., W.B.Z., Z.L., E.G., D.N.C. and C.F. contributed to the study 565 design and critically revised the manuscript with important intellectual input. All authors approved the 566 final manuscript submitted.

567

568 Acknowledgements

We are grateful to Peter C. Harris (Mayo Clinic and Foundation, Rochester, Minnesota) and KarenRaraigh (Johns Hopkins University, Baltimore, Maryland) for their prompt and positive replies to our

- 571 inquiries about using data from the ADPKD variant database and the CFTR2 database, respectively.
- 572

perpetuity. It is made available under a CC-BY-NC 4.0 International license .

573 **References**

- Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24.
- Johnston JJ, Brennan ML, Radenbaugh B, Yoo SJ, Hernandez SM, Core NRP, et al. The ACMG SF v3.0 gene list increases returnable variant detection by 22% when compared with v2.0 in the ClinSeq cohort. Genet Med. 2022;24(3):736-43.
- Kelly MA, Caleshu C, Morales A, Buchan J, Wolf Z, Harrison SM, et al. Adaptation and validation of the
 ACMG/AMP variant classification framework for *MYH7*-associated inherited cardiomyopathies:
 recommendations by ClinGen's Inherited Cardiomyopathy Expert Panel. Genet Med. 2018;20(3):351-9.
- Morales A, Kinnamon DD, Jordan E, Platt J, Vatta M, Dorschner MO, et al. Variant interpretation for dilated cardiomyopathy: refinement of the American College of Medical Genetics and Genomics/ClinGen Guidelines for the DCM Precision Medicine Study. Circ Genom Precis Med. 2020;13(2):e002480.
- Kountouris P, Stephanou C, Lederer CW, Traeger-Synodinos J, Bento C, Harteveld CL, et al. Adapting the
 ACMG/AMP variant classification framework: a perspective from the ClinGen Hemoglobinopathy Variant
 Curation Expert Panel. Hum Mutat. 2022;43(8):1089-96.
- Fortuno C, Mester J, Pesaran T, Weitzel JN, Dolinsky J, Yussuf A, et al. Suggested application of HER2+ breast tumor phenotype for germline *TP53* variant classification within ACMG/AMP guidelines. Hum Mutat. 2020;41(9):1555-62.
- 592 7. Lee K, Krempely K, Roberts ME, Anderson MJ, Carneiro F, Chao E, et al. Specifications of the ACMG/AMP
 593 variant curation guidelines for the analysis of germline *CDH1* sequence variants. Hum Mutat.
 594 2018;39(11):1553-68.
- Mester JL, Ghosh R, Pesaran T, Huether R, Karam R, Hruska KS, et al. Gene-specific criteria for *PTEN* variant curation: Recommendations from the ClinGen PTEN Expert Panel. Hum Mutat. 2018;39(11):1581-92.
- 597 9. Oza AM, DiStefano MT, Hemphill SE, Cushman BJ, Grant AR, Siegert RK, et al. Expert specification of the
 598 ACMG/AMP variant interpretation guidelines for genetic hearing loss. Hum Mutat. 2018;39(11):1593-613.
- Parsons MT, Tudini E, Li H, Hahnen E, Wappenschmidt B, Feliubadalo L, et al. Large scale multifactorial
 likelihood quantitative analysis of *BRCA1* and *BRCA2* variants: An ENIGMA resource to support clinical
 variant classification. Hum Mutat. 2019;40(9):1557-78.
- Brandt T, Sack LM, Arjona D, Tan D, Mei H, Cui H, et al. Adapting ACMG/AMP sequence variant classification
 guidelines for single-gene copy number variants. Genet Med. 2020;22(2):336-44.
- Nykamp K, Anderson M, Powers M, Garcia J, Herrera B, Ho YY, et al. Sherloc: a comprehensive refinement
 of the ACMG-AMP variant classification criteria. Genet Med. 2017;19(10):1105-17.
- I3. Zastrow DB, Baudet H, Shen W, Thomas A, Si Y, Weaver MA, et al. Unique aspects of sequence variant
 interpretation for inborn errors of metabolism (IEM): The ClinGen IEM Working Group and the
 Phenylalanine Hydroxylase Gene. Hum Mutat. 2018;39(11):1569-80.
- McCormick EM, Lott MT, Dulik MC, Shen L, Attimonelli M, Vitale O, et al. Specifications of the ACMG/AMP
 standards and guidelines for mitochondrial DNA variant interpretation. Hum Mutat. 2020;41(12):2028-57.
- Fortuno C, Lee K, Olivier M, Pesaran T, Mai PL, de Andrade KC, et al. Specifications of the ACMG/AMP variant
 interpretation guidelines for germline *TP53* variants. Hum Mutat. 2021;42(3):223-36.
- 613 16. Burdon KP, Graham P, Hadler J, Hulleman JD, Pasutto F, Boese EA, et al. Specifications of the ACMG/AMP
 614 variant curation guidelines for myocilin: Recommendations from the clingen glaucoma expert panel. Hum
 615 Mutat. 2022;43(12):2170-86.
- Margraf RL, Alexander RZ, Fulmer ML, Miller CE, Coupal E, Mao R. Multiple endocrine neoplasia type 2
 (MEN2) and *RET* specific modifications of the ACMG/AMP variant classification guidelines and impact on
 the MEN2 *RET* database. Hum Mutat. 2022;43(12):1780-94.
- Houge G, Laner A, Cirak S, de Leeuw N, Scheffer H, den Dunnen JT. Stepwise ABC system for classification
 of any type of genetic variant. Eur J Hum Genet. 2022;30(2):150-9.
- Masson E, Zou WB, Génin E, Cooper DN, Le Gac G, Fichou Y, et al. Expanding ACMG variant classification
 guidelines into a general framework. Hum Genomics. 2022;16(1):31.
- Audrézet MP, Cornec-Le Gall E, Chen JM, Redon S, Quéré I, Creff J, et al. Autosomal dominant polycystic
 kidney disease: comprehensive mutation analysis of *PKD1* and *PKD2* in 700 unrelated patients. Hum Mutat.
 2012;33(8):1239-50.
- 626 21. Cornec-Le Gall E, Audrézet MP, Chen JM, Hourmant M, Morin MP, Perrichot R, et al. Type of *PKD1* mutation
 627 influences renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006-13.

- 628 22. Cornec-Le Gall E, Audrézet MP, Le Meur Y, Chen JM, Férec C. Genetics and pathogenesis of autosomal
 629 dominant polycystic kidney disease: 20 years on. Hum Mutat. 2014;35(12):1393-406.
- Férec C, Audrezet MP, Mercier B, Guillermit H, Moullier P, Quere I, et al. Detection of over 98% cystic fibrosis
 mutations in a Celtic population. Nat Genet. 1992;1(3):188-91.
- 632 24. Férec C, Cutting GR. Assessing the disease-liability of mutations in *CFTR*. Cold Spring Harb Perspect Med.
 633 2012;2(12):a009480.
- Scotet V, L'Hostis C, Férec C. The changing epidemiology of cystic fibrosis: Incidence, survival and impact of
 the *CFTR* gene discovery. Genes (Basel). 2020;11(6).
- 636 26. Qorri E, Takacs B, Graf A, Enyedi MZ, Pinter L, Kiss E, et al. A comprehensive evaluation of the performance
 637 of prediction algorithms on clinically relevant missense variants. Int J Mol Sci. 2022;23(14).
- Raraigh KS, Han ST, Davis E, Evans TA, Pellicore MJ, McCague AF, et al. Functional assays are essential for
 interpretation of missense variants associated with variable expressivity. Am J Hum Genet.
 2018;102(6):1062-77.
- 641 28. ClinVar. <u>https://www.ncbi.nlm.nih.gov/clinvar/</u>. Accessed 28 December 2022.
- 642 29. Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet.
 643 2019;393(10174):919-35.
- 64430. HarrisPC,TorresVE.PolycysticKidneyDisease,AutosomalDominant.645https://www.ncbi.nlm.nih.gov/books/NBK1246/. Accessed 28 December 2022.
- The European Polycystic Kidney Disease Consortium. The polycystic kidney disease 1 gene encodes a 14 kb
 transcript and lies within a duplicated region on chromosome 16. Cell. 1994;77(6):881-94.
- 648 32. The ADPKD Variant Database. <u>https://pkdb.mayo.edu/</u>. Accessed 28 December 2022.
- 649 33. Paterson AD, Wang KR, Lupea D, St George-Hyslop P, Pei Y. Recurrent fetal loss associated with bilineal
 650 inheritance of type 1 autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2002;40(1):16-20.
- 34. Peces R, Peces C, Coto E, Selgas R. Bilineal inheritance of type 1 autosomal dominant polycystic kidney
 disease (ADPKD) and recurrent fetal loss. NDT Plus. 2008;1(5):289-91.
- Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan X, et al. Perinatal lethality with kidney and pancreas
 defects in mice with a targetted *Pkd1* mutation. Nat Genet. 1997;17(2):179-81.
- 465 36. Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, et al. Lowering of
 Pkd1 expression is sufficient to cause polycystic kidney disease. Hum Mol Genet. 2004;13(24):3069-77.
- 37. Jiang ST, Chiou YY, Wang E, Lin HK, Lin YT, Chi YC, et al. Defining a link with autosomal-dominant polycystic
 kidney disease in mice with congenitally low expression of *Pkd1*. Am J Pathol. 2006;168(1):205-20.
- 38. Vujic M, Heyer CM, Ars E, Hopp K, Markoff A, Orndal C, et al. Incompletely penetrant *PKD1* alleles mimic
 the renal manifestations of ARPKD. J Am Soc Nephrol. 2010;21(7):1097-102.
- 39. Rossetti S, Kubly VJ, Consugar MB, Hopp K, Roy S, Horsley SW, et al. Incompletely penetrant *PKD1* alleles
 suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney Int. 2009;75(8):848-55.
- 40. Reiterova J, Stekrova J, Merta M, Kotlas J, Elisakova V, Lnenicka P, et al. Autosomal dominant polycystic
 kidney disease in a family with mosaicism and hypomorphic allele. BMC Nephrol. 2013;14:59.
- 41. Bergmann C, von Bothmer J, Ortiz Bruchle N, Venghaus A, Frank V, Fehrenbach H, et al. Mutations in
 multiple *PKD* genes may explain early and severe polycystic kidney disease. J Am Soc Nephrol.
 2011;22(11):2047-56.
- 668 42. Gilbert RD, Sukhtankar P, Lachlan K, Fowler DJ. Bilineal inheritance of *PKD1* abnormalities mimicking
 autosomal recessive polycystic disease. Pediatr Nephrol. 2013;28(11):2217-20.
- 43. Hopp K, Ward CJ, Hommerding CJ, Nasr SH, Tuan HF, Gainullin VG, et al. Functional polycystin-1 dosage
 governs autosomal dominant polycystic kidney disease severity. J Clin Invest. 2012;122(11):4257-73.
- 44. Ali H, Hussain N, Naim M, Zayed M, Al-Mulla F, Kehinde EO, et al. A novel *PKD1* variant demonstrates a
 disease-modifying role in trans with a truncating PKD1 mutation in patients with autosomal dominant
 polycystic kidney disease. BMC Nephrol. 2015;16:26.
- 45. Pandita S, Khullar D, Saxena R, Verma IC. Autosomal dominant polycystic kidney disease: presence of
 hypomorphic alleles in *PKD1* gene. Indian J Nephrol. 2018;28(6):482-4.
- 46. Al-Hamed MH, Alsahan N, Rice SJ, Edwards N, Nooreddeen E, Alotaibi M, et al. Bialleleic *PKD1* mutations
 underlie early-onset autosomal dominant polycystic kidney disease in Saudi Arabian families. Pediatr
 Nephrol. 2019;34(9):1615-23.
- de Fallois J, Schonauer R, Munch J, Nagel M, Popp B, Halbritter J. Challenging disease ontology by instances
 of atypical *PKHD1* and *PKD1* genetics. Front Genet. 2021;12:682565.
- 48. Durkie M, Chong J, Valluru MK, Harris PC, Ong ACM. Biallelic inheritance of hypomorphic *PKD1* variants is
 highly prevalent in very early onset polycystic kidney disease. Genet Med. 2021;23(4):689-97.

- 684 Finnegan C, Murphy C, Breathnach F. Neonatal polycystic kidney disease: a novel variant. BMJ Case Rep. 49. 685 2021;14(7).
- 686 50. Cornec-Le Gall E, Torres VE, Harris PC. Genetic complexity of autosomal dominant polycystic kidney and 687 liver diseases. J Am Soc Nephrol. 2018;29(1):13-23.
- 688 51. Misra S, Hassanali N, Bennett AJ, Juszczak A, Caswell R, Colclough K, et al. Homozygous hypomorphic HNF1A 689 alleles are a novel cause of young-onset diabetes and result in sulfonylurea-sensitive diabetes. Diabetes 690 Care. 2020;43(4):909-12.
- 691 52. Patel KA, Kettunen J, Laakso M, Stancakova A, Laver TW, Colclough K, et al. Heterozygous RFX6 protein 692 truncating variants are associated with MODY with reduced penetrance. Nat Commun. 2017;8(1):888.
- 693 53. Laver TW, Colclough K, Shepherd M, Patel K, Houghton JA, Dusatkova P, et al. The common p.R114W HNF4A 694 mutation causes a distinct clinical subtype of monogenic diabetes. Diabetes. 2016;65(10):3212-7.
- 695 54. Sharma M, Ioannidis JP, Aasly JO, Annesi G, Brice A, Bertram L, et al. A multi-centre clinico-genetic analysis 696 of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. J Med 697 Genet. 2012;49(11):721-6.
- 698 55. Sierra M, Gonzalez-Aramburu I, Sanchez-Juan P, Sanchez-Quintana C, Polo JM, Berciano J, et al. High 699 frequency and reduced penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in 700 Cantabria (Spain). Mov Disord. 2011;26(13):2343-6.
- 701 Bauwens M, Garanto A, Sangermano R, Naessens S, Weisschuh N, De Zaeytijd J, et al. ABCA4-associated 56. 702 disease as a model for missing heritability in autosomal recessive disorders: novel noncoding splice, cis-703 regulatory, structural, and recurrent hypomorphic variants. Genet Med. 2019;21(8):1761-71.
- 704 57. De Mori R, Romani M, D'Arrigo S, Zaki MS, Lorefice E, Tardivo S, et al. Hypomorphic recessive variants in 705 SUFU impair the sonic hedgehog pathway and cause Joubert syndrome with cranio-facial and skeletal 706 defects. Am J Hum Genet. 2017;101(4):552-63.
- 707 58. Whiffin N, Minikel E, Walsh R, O'Donnell-Luria AH, Karczewski K, Ing AY, et al. Using high-resolution variant 708 frequencies to empower clinical genome interpretation. Genet Med. 2017;19(10):1151-8.
- 709 Ragoussis V, Pagnamenta AT, Haines RL, Giacopuzzi E, McClatchey MA, Sampson JR, et al. Using data from 59. 710 the 100,000 Genomes Project to resolve conflicting interpretations of a recurrent TUBB2A mutation. J Med 711 Genet. 2022;59(4):366-9.
- 712 60. Hanany M, Sharon D. Allele frequency analysis of variants reported to cause autosomal dominant inherited 713 retinal diseases question the involvement of 19% of genes and 10% of reported pathogenic variants. J Med 714 Genet. 2019;56(8):536-42.
- 715 61. Kobayashi Y, Yang S, Nykamp K, Garcia J, Lincoln SE, Topper SE. Pathogenic variant burden in the ExAC 716 database: an empirical approach to evaluating population data for clinical variant interpretation. Genome 717 Med. 2017;9(1):13.
- 718 Minikel EV, MacArthur DG. Publicly available data provide evidence against NR1H3 R415Q causing multiple 62. 719 sclerosis. Neuron. 2016;92(2):336-8.
- 720 Solazzo A, Testa F, Giovanella S, Busutti M, Furci L, Carrera P, et al. The prevalence of autosomal dominant 63. 721 polycystic kidney disease (ADPKD): A meta-analysis of European literature and prevalence evaluation in the 722 Italian province of Modena suggest that ADPKD is a rare and underdiagnosed condition. PLoS One. 723 2018;13(1):e0190430.
- 724 64. Willey C, Kamat S, Stellhorn R, Blais J. Analysis of nationwide data to determine the incidence and diagnosed 725 prevalence of autosomal dominant polycystic kidney disease in the USA: 2013-2015. Kidney Dis (Basel). 726 2019;5(2):107-17.
- 727 65. gnomAD (Genome Aggregation Database). https://gnomad.broadinstitute.org/. Accessed 28 December 728 2022.
- 729 66. Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397(10290):2195-211.
- 730 67. Kerem B, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, et al. Identification of the cystic 731 fibrosis gene: genetic analysis. Science. 1989;245(4922):1073-80.
- 732 68. The Cystic Fibrosis Mutation Database (CFTR1). http://www.genet.sickkids.on.ca/. Accessed 28 December 733 2022.
- 734 69. The Clinical and Functional TRanslation of CFTR (CFTR2) databse. https://cftr2.org/. Accessed 28 December 735 2022.
- 736 70. Knowles MR, Drumm M. The influence of genetics on cystic fibrosis phenotypes. Cold Spring Harb Perspect 737 Med. 2012;2(12):a009548.
- 738 Raraigh KS, Aksit MA, Hetrick K, Pace RG, Ling H, O'Neal W, et al. Complete CFTR gene sequencing in 5,058 71. 739 individuals with cystic fibrosis informs variant-specific treatment. J Cyst Fibros. 2022;21(3):463-70.

- 740
 72. Izquierdo ME, Marion CR, Moore WC, Raraigh KS, Taylor-Cousar JL, Cutting GR, et al. DNA sequencing analysis of cystic fibrosis transmembrane conductance regulator gene identifies cystic fibrosis-associated variants in the Severe Asthma Research Program. Pediatr Pulmonol. 2022;57(7):1782-8.
 742
 743
 744
 744
 745
 745
 745
 746
 747
 748
 748
 749
 749
 749
 740
 740
 740
 741
 741
 742
 743
 744
 744
 744
 745
 745
 745
 746
 747
 747
 748
 748
 749
 749
 749
 740
 741
 741
 741
 741
 742
 743
 744
 744
 744
 744
 745
 744
 745
 745
 745
 746
 747
 747
 748
 748
 748
 749
 749
 749
 740
 741
 741
 741
 741
 744
 744
 744
 745
 744
 744
 744
 745
 744
 744
 745
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744
 744<
- 743 73. Sermet-Gaudelus I, Girodon E, Vermeulen F, Solomon GM, Melotti P, Graeber SY, et al. ECFS standards of
 744 care on CFTR-related disorders: Diagnostic criteria of CFTR dysfunction. J Cyst Fibros. 2022;21(6):922-36.
- 74. Lyon MF. Sex chromatin and gene action in the mammalian X-chromosome. Am J Hum Genet.
 746 1962;14(2):135-48.
- 747 75. Shvetsova E, Sofronova A, Monajemi R, Gagalova K, Draisma HHM, White SJ, et al. Skewed X-inactivation is
 748 common in the general female population. Eur J Hum Genet. 2019;27(3):455-65.
- 76. Dobyns WB, Filauro A, Tomson BN, Chan AS, Ho AW, Ting NT, et al. Inheritance of most X-linked traits is not dominant or recessive, just X-linked. Am J Med Genet A. 2004;129A(2):136-43.
- 751 77. Bhanushali AA, Mandsaurwala A, Das BR. Homozygous c.1160C>T (P38L) in the *MECP2* gene in a female
 752 Rett syndrome patient. J Clin Neurosci. 2016;25:127-9.
- 753 78. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations
 754 in X-linked *MECP2*, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23(2):185-8.
- 755 79. Philippe C, Villard L, De Roux N, Raynaud M, Bonnefond JP, Pasquier L, et al. Spectrum and distribution of
 756 *MECP2* mutations in 424 Rett syndrome patients: a molecular update. Eur J Med Genet. 2006;49(1):9-18.
- 75780. The Genetic and Rare Diseases (GARD) Information Center Website: Rett syndrome.758https://rarediseases.info.nih.gov/diseases/5696/rett-syndrome. Accessed 28 December 2022.
- 759 81. Villard L. *MECP2* mutations in males. J Med Genet. 2007;44(7):417-23.
- 760 82. Couvert P, Bienvenu T, Aquaviva C, Poirier K, Moraine C, Gendrot C, et al. *MECP2* is highly mutated in X 761 linked mental retardation. Hum Mol Genet. 2001;10(9):941-6.
- 762 83. Laccone F, Zoll B, Huppke P, Hanefeld F, Pepinski W, Trappe R. *MECP2* gene nucleotide changes and their
 763 pathogenicity in males: proceed with caution. J Med Genet. 2002;39(8):586-8.
- Petriti U, Dudman DC, Scosyrev E, Lopez-Leon S. Global prevalence of Rett syndrome: systematic review
 and meta-analysis. Syst Rev. 2023;12(1):5.
- 85. Barboza-Cerda MC, Wong LJ, Martinez-de-Villarreal LE, Zhang VW, Dector MA. A novel *EBP* c.224T>A
 mutation supports the existence of a male-specific disorder independent of CDPX2. Am J Med Genet A.
 2014;164A(7):1642-7.
- Popp B, Stove SI, Endele S, Myklebust LM, Hoyer J, Sticht H, et al. De novo missense mutations in the *NAA10*gene cause severe non-syndromic developmental delay in males and females. Eur J Hum Genet.
 2015;23(5):602-9.
- Ragge N, Isidor B, Bitoun P, Odent S, Giurgea I, Cogne B, et al. Expanding the phenotype of the X-linked
 BCOR microphthalmia syndromes. Hum Genet. 2019;138(8-9):1051-69.
- 88. du Souich C, Raymond FL, Grzeschik KH, Boerkoel CF. *NSDHL*-Related Disorders.
 https://pubmed.ncbi.nlm.nih.gov/21290788/. Accessed 28 December 2022.
- 89. Boisson B, Honda Y, Ajiro M, Bustamante J, Bendavid M, Gennery AR, et al. Rescue of recurrent deep intronic
 mutation underlying cell type-dependent quantitative NEMO deficiency. J Clin Invest. 2019;129(2):583-97.
- 90. Nicola P, Blackburn PR, Rasmussen KJ, Bertsch NL, Klee EW, Hasadsri L, et al. *De novo DDX3X* missense variants in males appear viable and contribute to syndromic intellectual disability. Am J Med Genet A. 2019;179(4):570-8.
- 91. Moog U, Kutsche K. CASK Disorders. <u>https://pubmed.ncbi.nlm.nih.gov/24278995/</u>. Accessed 28 December
 2022.
- 783 92. The Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that
 784 is expanded and unstable on Huntington's disease chromosomes. Cell. 1993;72(6):971-83.
- 785 93. Cubo E, Martinez-Horta SI, Santalo FS, Descalls AM, Calvo S, Gil-Polo C, et al. Clinical manifestations of
 786 homozygote allele carriers in Huntington disease. Neurology. 2019;92(18):e2101-e8.
- 787 94. Walker FO. Huntington's disease. Lancet. 2007;369(9557):218-28.
- Verkerk AJ, Pieretti M, Sutcliffe JS, Fu YH, Kuhl DP, Pizzuti A, et al. Identification of a gene (*FMR-1*) containing
 a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome.
 Cell. 1991;65(5):905-14.
- 96. Willemsen R, Levenga J, Oostra BA. CGG repeat in the *FMR1* gene: size matters. Clin Genet. 2011;80(3):21425.
- 793 97. Mesinele J, Ruffin M, Guillot L, Corvol H. Modifier factors of cystic fibrosis phenotypes: a focus on modifier
 794 genes. Int J Mol Sci. 2022;23(22).
- P8. Chang AR, Moore BS, Luo JZ, Sartori G, Fang B, Jacobs S, et al. Exome sequencing of a clinical population for autosomal dominant polycystic kidney disease. JAMA. 2022;328(24):2412-21.

- 99. Herzig AF, Genin E, Cooper DN, Masson E, Férec C, Chen JM. Role of the common *PRSS1-PRSS2* haplotype
 in alcoholic and non-alcoholic chronic pancreatitis: Meta- and re-analyses. Genes (Basel). 2020;11(11):1349.
- Yao Q, Gorevic P, Shen B, Gibson G. Genetically transitional disease: a new concept in genomic medicine.
 Trends Genet. 2022.
- 101. Papadimitriou S, Gravel B, Nachtegael C, De Baere E, Loeys B, Vikkula M, et al. Toward reporting standards
 for the pathogenicity of variant combinations involved in multilocus/oligogenic diseases. HGG Adv.
 2023;4(1):100165.
- 102. Chakravarti A. Magnitude of Mendelian versus complex inheritance of rare disorders. Am J Med Genet A.
 2021;185(11):3287-93.
- 806 103. Pounraja VK, Girirajan S. A general framework for identifying oligogenic combinations of rare variants in complex disorders. Genome Res. 2022;32(5):904-15.
- 808 104. Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability
 809 of complex diseases. Nature. 2009;461(7265):747-53.
- 810 105. Génin E. Missing heritability of complex diseases: case solved? Hum Genet. 2020;139(1):103-13.
- 811 106. ClinGen Low-Penetrance/Risk Allele Working Group. <u>https://clinicalgenome.org/working-groups/low-penetrance-risk-allele-working-group/</u>. Accessed 28 December 2022.
- 813 107. Masson E, Chen JM, Audrézet MP, Cooper DN, Férec C. A conservative assessment of the major genetic
 814 causes of idiopathic chronic pancreatitis: data from a comprehensive analysis of *PRSS1*, *SPINK1*, *CTRC* and
 815 *CFTR* genes in 253 young French patients. PLoS One. 2013;8(8):e73522.
- 816 108. Hu C, Susswein LR, Roberts ME, Yang H, Marshall ML, Hiraki S, et al. Classification of *BRCA2* variants of 817 uncertain significance (VUS) using an ACMG/AMP model incorporating a homology-directed repair (HDR) 818 functional assay. Clin Cancer Res. 2022;28(17):3742-51.
- 819 109. Coursimault J, Goldenberg A, Nicolas G, Saugier-Veber P, Coutant S, Vincent A, et al. Contribution of DNA
 820 methylation profiling to the reclassification of a variant of uncertain significance in the *KDM5C* gene. Eur J
 821 Med Genet. 2022;65(9):104556.
- Bjelos M, Busic M, Curic A, Bosnar D, Saric B, Markovic L, et al. Pathogenicity reclassification of the *RPE65* c.1580A>G (p.His527Arg) a case report. Ophthalmic Genet. 2022:1-5.
- 111. Micale L, Russo F, Mascaro M, Morlino S, Nardella G, Fusco C, et al. Opitz syndrome: improving clinical
 interpretation of intronic variants in *MID1* gene. Pediatr Res. 2022.
- Kurolap A, Mory A, Simchoni S, Krajden Haratz K, Malinger G, Birnbaum R, et al. Upgrading an intronic
 TMEM67 variant of unknown significance to likely pathogenic through RNA studies and community data
 sharing. Prenat Diagn. 2022;42(12):1484-7.
- 113. Copier JS, Bootsma M, Ng CA, Wilde AAM, Bertels RA, Bikker H, et al. Reclassification of a likely pathogenic
 Dutch founder variant in *KCNH2*; implications of reduced penetrance. Hum Mol Genet. 2022.
- He W, Meng G, Hu X, Dai J, Liu J, Li X, et al. Reclassification of *DMD* duplications as benign: recommendations
 for cautious interpretation of variants identified in prenatal screening. Genes (Basel). 2022;13(11).
- 115. Makhnoon S, Levin B, Ensinger M, Mattie K, Volk RJ, Zhao Z, et al. A multicenter study of clinical impact of
 variant of uncertain significance reclassification in breast, ovarian and colorectal cancer susceptibility genes.
 Cancer Med. 2022.
- 836 116. Scott A, Hernandez F, Chamberlin A, Smith C, Karam R, Kitzman JO. Saturation-scale functional evidence
 837 supports clinical variant interpretation in Lynch syndrome. Genome Biol. 2022;23(1):266.
- 838 117. Bang YJ, Kwon WK, Kim JW, Lee JE, Jung BY, Kim M, et al. Comprehensive clinical characterization of patients
 839 with *BRCA1*: c.5017_5019del germline variant. Ann Surg Treat Res. 2022;103(6):323-30.
- 118. Dong Z, Wang Y, Zhang J, Zhu F, Liu Z, Kang Y, et al. Analyzing the effects of *BRCA1/2* variants on mRNA
 splicing by minigene assay. J Hum Genet. 2022.